Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 20

Results For "biopharmaceutical-company"

277 News Found

BSV receives exclusive marketing and distribution right for NexoBrid in India
Supply Chain | December 14, 2022

BSV receives exclusive marketing and distribution right for NexoBrid in India

To focus on providing safer burn treatments for women and armed forces


Peter Bains appointed Additional Director of Biocon
People | December 13, 2022

Peter Bains appointed Additional Director of Biocon

He has global experience in strategic and operational leadership including at Board, CEO and Senior Corporate levels


Evonik invests in US based biopharma company ‘Allay Therapeutics’
News | December 13, 2022

Evonik invests in US based biopharma company ‘Allay Therapeutics’

Implants from the U.S. startup Allay Therapeutics are designed to relieve pain after knee surgery for up to three weeks


AstraZeneca receives import and market permission from CDSCO for Dapagliflozin
Drug Approval | November 26, 2022

AstraZeneca receives import and market permission from CDSCO for Dapagliflozin

The receipt of this permission paves way for the launch of Dapagliflozin (Forxiga) tablets of 10 mg in India for the specified additional/expanded indication, subject to the receipt of related statutory approvals


Biocon enters commercialization agreement with Zentiva
News | November 24, 2022

Biocon enters commercialization agreement with Zentiva

Under the terms of this agreement Biocon will be responsible for the manufacturing and supply of Liraglutide to Zentiva, for its commercialization across 30 countries in Europe


Evive enters license agreement with Acrotech Biopharma to commercialize Ryzneuta in US
News | November 24, 2022

Evive enters license agreement with Acrotech Biopharma to commercialize Ryzneuta in US

Ryzneuta is a novel dimeric G- CSF long-acting fusion protein without pegylation. The Biologics License Application (BLA) of Ryzneuta is currently under late-stage review by the US FDA for Chemotherapy-Induced Neutropenia (CIN)


Merck to acquire Imago BioSciences for $1.35 bn
News | November 22, 2022

Merck to acquire Imago BioSciences for $1.35 bn

Acquisition expands Merck’s growing hematology portfolio


USFDA determines inspection classification of Jubilant Pharmova's Roorkee facility
News | October 31, 2022

USFDA determines inspection classification of Jubilant Pharmova's Roorkee facility

The company currently supplies one product to the US market that contributes low- single digit revenue to Jubilant Pharmova revenue


ERES IV acquires a majority stake in Oncodesign Services
News | October 27, 2022

ERES IV acquires a majority stake in Oncodesign Services

Oncodesign Services (ODS ), with 600 clients in 33 countries and 227 employees worldwide, provides services from target identification to hit-to-lead and lead optimization through to IND filing.


Inceptua Early Access and Sentynl Therapeutics launch early access program for Nulibry for pediatric patients
News | October 19, 2022

Inceptua Early Access and Sentynl Therapeutics launch early access program for Nulibry for pediatric patients

MoCD Type A is a rapidly progressive autosomal recessive inborn error of metabolism resulting in toxic sulfite levels causing neurologic sequelae